MEI Stock Based Compensation To Revenue from 2010 to 2024
| MEIP Stock | USD 2.70 0.10 3.57% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 0.03488675 | Current Value 0.0331 | Quarterly Volatility 0.55618506 |
Check MEI Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MEI Pharma's main balance sheet or income statement drivers, such as Interest Expense of 310.3 K, Selling General Administrative of 24.5 M or Total Revenue of 68.6 M, as well as many indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.49 or PTB Ratio of 0.55. MEI financial statements analysis is a perfect complement when working with MEI Pharma Valuation or Volatility modules.
MEI | Stock Based Compensation To Revenue |
Latest MEI Pharma's Stock Based Compensation To Revenue Growth Pattern
Below is the plot of the Stock Based Compensation To Revenue of MEI Pharma over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. MEI Pharma's Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MEI Pharma's overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation To Revenue | 10 Years Trend |
|
Stock Based Compensation To Revenue |
| Timeline |
MEI Stock Based Compensation To Revenue Regression Statistics
| Arithmetic Mean | 0.35 | |
| Geometric Mean | 0.16 | |
| Coefficient Of Variation | 157.68 | |
| Mean Deviation | 0.36 | |
| Median | 0.1 | |
| Standard Deviation | 0.56 | |
| Sample Variance | 0.31 | |
| Range | 1.9503 | |
| R-Value | (0.01) | |
| Mean Square Error | 0.33 | |
| R-Squared | 0.000035 | |
| Significance | 0.98 | |
| Slope | (0.0007) | |
| Total Sum of Squares | 4.33 |
MEI Stock Based Compensation To Revenue History
About MEI Pharma Financial Statements
MEI Pharma shareholders use historical fundamental indicators, such as Stock Based Compensation To Revenue, to determine how well the company is positioned to perform in the future. Although MEI Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in MEI Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on MEI Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 0.03 | 0.03 |
Pair Trading with MEI Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MEI Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MEI Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against MEI Stock
| 0.55 | FLGC | Flora Growth Corp | PairCorr |
| 0.37 | DYAI | Dyadic International | PairCorr |
| 0.35 | DNA | Ginkgo Bioworks Holdings | PairCorr |
| 0.32 | ESPR | Esperion Therapeutics | PairCorr |
| 0.32 | IMAB | I Mab | PairCorr |
The ability to find closely correlated positions to MEI Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MEI Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MEI Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MEI Pharma to buy it.
The correlation of MEI Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MEI Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MEI Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MEI Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.